Trunome

Agragesh Ramani and Avinash Ramani are Season 2's most deeply credentialled genomics diagnostics founding brothers researchers and scientists who spent nearly a decade developing a patented liquid biopsy platform for chronic disease monitoring before appearing on Shark Tank India. The Ramani brothers' nine-year development timeline (2014 to 2023) reflects the specific regulatory and clinical validation requirements of a diagnostic medical device not a consumer product that can be iterated quickly based on market feedback. Their technology had to clear CDSCO regulatory review, achieve clinical validation secure hospital partnerships, and attract world-renowned medical specialists as shareholders before commercial scaling was possible.

The founders conveyed that there are 2 lakh patients in India with chronic disease organ transplants and their number increases by 40K per year. Organ transplant is a painful and traumatic experience, and unfortunately, their pain continues even after the transplant. After an organ transplant, the patients need continuous monitoring of the new organ for which they need a regular biopsy, which is very expensive, painful, and risky as well. To solve this, the founders have built a revolutionary platform, that is Trunome. Trunome is a patented technology through which chronic diseases can get diagnosed earlier by just doing a blood test, and monitoring them easily too. It can also early detect cancer and can cure grave diseases earlier. They have tested 5K+ samples, and 1,500+ lives were impacted. Their vision is to impact 1 billion patients life through Trunome.

Amount Asked: ₹1.5 crore Equity Offered: 1% Implied Pre-Money Valuation: ₹150 crore

Agragesh and Avinash opened Season 2 Episode 41 with India's most medically urgent diagnostic problem: organ transplant patients who, after surviving the trauma of a major organ transplant, must endure regular painful and expensive biopsies for the rest of their lives to monitor whether their new organ is being rejected. The emotional weight of this problem patients who have already suffered one of medicine's most extreme interventions continuing to suffer for monitoring made the pitch's medical impact statement immediately comprehensible to every Shark and every viewer. The technology demonstration explaining how a blood test replaces a tissue biopsy while achieving 100 percent accuracy was the pitch's most scientifically precise claim and simultaneously its most commercially compelling. A diagnostic that achieves equivalent or superior accuracy at 84 percent lower cost while eliminating the procedure's physical pain entirely has an obviously enormous market opportunity.

Namita Thapar was the most medically informed Shark and the most commercially sceptical. Peyush Bansal made the first formal offer ₹1.5 crore for 2% equity, immediately setting the deal's financial terms. Anupam Mittal suggested the same amount for 1.75% equity attempting to marginally improve the founders' equity position while matching the capital. Aman Gupta and Vineeta Singh joined the coalition forming the four-Shark offer of ₹1.5 crore for 2% equity.

Finally, four sharks Peyush, Anupam, Vineeta, and Aman gave Trunome owners an offer of 1.5 crores for 2% equity, to which they counter-proposed 3 crores for 2.5% equity. The final deal was closed with Anupam, Peyush, Aman and Vineeta at ₹1.5 crores for 2% equity

Agragesh Ramani and Avinash Ramani accepted the four-Shark joint offer of ₹1.5 crore for 2% equity from Anupam Mittal, Vineeta Singh, Aman Gupta, and Peyush Bansal valuing Trunome at ₹75 crore post-deal. The founders' counter of ₹3 crore for 2.5% equity was declined and the Sharks' original terms were accepted. Deal closure confirmation post-show is unclear as the company has rebranded to Acrannolife Genomics.

Trunome Founders: Agragesh Ramani and Avinash Ramani Valuation/Networth: ₹150 Crore Funding: ₹1.5 crores for 2% Equity Shark Tank Season 2 Episode 41. They have raised another round just a month and a half before their pitch at valuation of ₹75 Crores. They are expecting the revenue of ₹4000 Crores. Company is also tying up with 5 major transplant hospitals in the states. The company rebranded from Trunome to Acrannolife Genomics after the Shark Tank episode aired. The US expansion targeting 5 major transplant hospitals represents the most commercially significant geographic expansion possible: the US organ transplant monitoring market is significantly larger and better-reimbursed than India's, and CDSCO clearance provides the regulatory credibility foundation for pursuing FDA clearance.